Steven M. Lieberman

Steven Lieberman

Rothwell Figg Ernst & Manbeck, P.C.

1425 K St NW, Suite 800
Washington, DC 20005

Contact Steven M. Lieberman

T: 202-783-6040

F: 202-783-6031

Visit: www.rothwellfigg.com

Practice areas: Intellectual Property Litigation (50%), Intellectual Property (30%), First Amendment/Media/Advertising (20%)

Law School: Columbia Law School

Profile

In the area of patent litigation, Mr. Lieberman has handled a variety of lawsuits in the pharmaceutical, biotech, veterinary, and medical products fields in both the district courts (and on appeal) and before the International Trade Commission. These actions include representing Burroughs Wellcome Co. in a number of lawsuits including actions relating to AZT (Retrovir) as a therapy for humans infected with the virus that causes AIDS; Zeneca Inc. in an action relating to its prostate cancer therapy Casodex; and Mylan Pharmceuticals Inc. in actions relating to, inter alia, buspirone, nifedipine, nitroglycerin patches, diltiazem, amlodipine and cimetidine. Mr. Lieberman also regularly represents clients on intellectual property matters relating to electronic commerce. Mr. Lieberman's clients in this area include both Fortune 500 companies and Internet start-up entities. For example, Mr. Lieberman currently represents The New York Times Company, Dow Jones, and the McGraw-Hill Companies in litigation or litigation-related matters. He also advises companies with respect to evaluation of potentially patentable inventions, strategic planning for protecting intellectual property relating to Internet businesses, and potential infringement issues.

Selected to Super Lawyers

Washington, D.C. Super Lawyers 2008
Washington, D.C. Super Lawyers 2007

About Steven Lieberman

Admitted: 1985, Washington D.C.

Honors and Awards: Selected by Law & Politics in 2007 as a Washington, D.C. Super Lawyer in the field of intellectual property litigation. Honored in 2006 by Ohev Sholom - The National Synagogue and in 2007 by Yeshivat Chovevei Torah for his work on behalf of those organizations.

Bar/Professional Activity: Past President of the Giles S. Rich American Inn of Court, the D.C. Inn devoted to the practice of intellectual property law. Past Chairman of the Defamation and New Technologies Subcommittee of the Committee on Media Law of the New York State Bar Association. Past Chairman of the Media Law Resource Center Cyberspace Committee. Member of Editorial Advisory Board for BNA's Pharmaceutical Law & Industry Report.

Pro bono/Community Service: Serves on the boards of a number of non-profit organizations including the Beth Sholom Congregation and Talmud Torah, Yeshivat Chovevei Torah, the Association for Safe International Road Travel, and the Charles E. Smith Jewish Day School (2000-2006).

Scholarly Lectures and Writings: Edited two collections of articles on Internet defamation issues for the New York State Bar Association and the MLRC. Commentator on TV/radio on First Amendment issues. Guest Speaker, Food and Drug Law Institute ("FDLI") Enforcement and Litigation Issues in Drug and Medical Device Law: Trouble in Court and How to Stay Out of It by FDLI (2002). Guest Lecturer, Institute for International Research Conference on Generic Drugs (2002); Breakout Session Leader, NAA/NAB/LDRC Libel Conference (Cyberlaw) (1997, 1999, 2002). Invited Speaker, Georgetown Law School, Hatch-Waxman Act (2002); Invited Speaker, Syracuse University College of Law, Patent Policy in the Pharmaceutical Industry (2003). Invited Speaker, FDLI, FDA's New Rule on Patent Listing Requirements and 30-Month Stays (2003). Guest Speaker, Global Generics Strategy Summit: The Battle for "Authorized Generics": Is There a Future? (2007); and Invited Speaker for the IP Organizing Subcommittee of the Maryland State Bar Association: A Trademark as a Sponsored Link: Is it an Actionable "Trademark Use" and is it Infringement? (2007).

Verdicts and Settlements: Mr. Lieberman's representation of Mylan in its patent and antitrust actions against Bristol-Myers Squibb arising from Bristol's improper listing of a buspirone metabolite patent in the Orange Book recently resulted in Bristol paying $535 million to settle antitrust claims brought against it by Mylan, 29 state Attorneys General, and private class action plaintiffs. Mr. Lieberman recently obtained a judgment of willful infringement for an e-commerce client that had sued a competitor for copying several of its online advertisements. In addition to finding willful infringement following a bench trial, the Court awarded Mr. Lieberman's client both statutory damages and more than $250,000 in attorneys' fees and costs.Mr. Lieberman represented Rabbi Avi Weiss in a two week jury trial in the District of Columbia against Howard University arising out of Howard's failure to protect Rabbi Weiss' right to protest speeches by of Khalid Abdul Mohammed at Howard University's campus, obtaining a jury verdict and judgment for Rabbi Weiss.

Representative Clients: The New York Times Company; Dow Jones; Disney; AstraZeneca; Mylan Pharmaceuticals; ITG, Inc.; Northrop Grumman, McGraw-Hill.

Other Outstanding Achievements: Co-author, District of Columbia section of the Media Law Resource Center's annual 50-State Survey of Media Privacy and Related Law (1993-2007 editions).

Get a Super Lawyers personalized badge for your website!

Map Location

Get Directions

What is Super Lawyers

Super Lawyers magazine names attorneys in each state who received the highest point totals, as chosen by their peers and through the independent research of Law & Politics. Rising Stars names the state's top up-and-coming attorneys.

Super Lawyers magazine is published in all 50 states and reaches more than 13 million readers.